Xeltis
Date | Investors | Amount | Round |
---|---|---|---|
N/A | Spinout | ||
$34.0m | Series B | ||
€3.0m | Series B | ||
€450k | Grant | ||
* | €45.0m | Series C | |
* | $11.7m Valuation: $237m | Series D | |
€2.5m | Grant | ||
* | €15.0m Valuation: €225m | Debt | |
* | €15.0m Valuation: €225m | Series D | |
* | €32.0m Valuation: €225m | Series D | |
* | €12.5m Valuation: €225m | Series D | |
Total Funding | €152m |
Recent News about Xeltis
EditDeveloper of medical devices designed to provide a restorative approach to cardiovascular therapy. The company's device comprises bioabsorbable heart valves and blood vessels designed to allow endogenous tissue restoration which is the natural restoration of the complex body part that gets replaced upon implantation, enabling the patient's body to naturally restore a new blood vessel or heart valve through a therapeutic approach.
Keywords: Healthcare Devices, Services, Supplies, Biodegradable Heart Valve, Coronary Bypass, Dialysis Access, Endogenous Tissue Growth, Heart Surgery, Medical Device, Medical Device Company, Vascular Disease Treatment, Vascular Surgery.